Gala Pharmaceutical Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements
Gala Pharmaceutical Inc. reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements of $22.93 thousand for the 6-month period ending 2019-05-31, per its 10-Q filed 2019-07-23.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements · last filed 2019-07-23
- Gala Pharmaceutical Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, settlements for the quarter ending 2019-05-31 was $0.00.
- Gala Pharmaceutical Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, settlements for the quarter ending 2019-02-28 was $22.93K.
- Gala Pharmaceutical Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, settlements for fiscal 2018 was $374.87K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements 12 month |
|---|---|---|---|
| 2019-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-23 | $22.93K 10-Q · filed 2019-07-23 | |
| 2019-02-28 | $22.93K 10-Q · filed 2019-04-30 | ||
| 2018-11-30 | $374.87K 10-K · filed 2019-04-15 |